Equities Analysts Offer Predictions for KYTX FY2029 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Kyverna Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($4.19) per share for the year. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.01. The company had revenue of $0.01 million for the quarter.

Other equities analysts also recently issued research reports about the stock. HC Wainwright cut their price objective on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a "neutral" rating on the stock in a report on Wednesday, November 20th. Wells Fargo & Company reduced their price target on Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $25.71.

Kyverna Therapeutics Price Performance

NASDAQ KYTX traded down $0.04 on Friday, hitting $2.98. The stock had a trading volume of 125,338 shares, compared to its average volume of 393,079. Kyverna Therapeutics has a 52-week low of $2.91 and a 52-week high of $30.60. The business's fifty day moving average price is $3.86 and its 200 day moving average price is $5.35.

Institutional Trading of Kyverna Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of KYTX. Novo Holdings A S increased its position in shares of Kyverna Therapeutics by 5.7% during the third quarter. Novo Holdings A S now owns 1,850,000 shares of the company's stock worth $9,046,000 after purchasing an additional 100,000 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Kyverna Therapeutics by 15.8% during the third quarter. JPMorgan Chase & Co. now owns 2,387,352 shares of the company's stock worth $11,674,000 after purchasing an additional 326,095 shares in the last quarter. FMR LLC acquired a new stake in shares of Kyverna Therapeutics during the third quarter worth about $33,000. Millennium Management LLC increased its position in shares of Kyverna Therapeutics by 32.8% during the second quarter. Millennium Management LLC now owns 923,082 shares of the company's stock worth $6,923,000 after purchasing an additional 227,988 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Kyverna Therapeutics by 21.5% during the third quarter. Barclays PLC now owns 70,167 shares of the company's stock worth $343,000 after purchasing an additional 12,418 shares in the last quarter. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.